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A B S T R A C T
Since 1990, sixteen new antiepileptic drugs (AEDs) have been introduced. Most of these new AEDs have
only been insufﬁciently studied with respect to women-speciﬁc aspects such as endogenous sex
hormones, hormonal contraception, pregnancy, breastfeeding, or menopause. This is of concern because
it has been shown for some of the new AEDs that these factors may have a clinically signiﬁcant impact on
their pharmacokinetics and seizure control. Also, new AEDs may affect hormone homeostasis and pass
over into breast milk. The best studied of the new AEDs are lamotrigine, levetiracetam and
oxcarbazepine. Although gabapentin and pregabalin are even more frequently used (due to their
therapeutic effects in nonepileptic conditions), our understanding of these two drugs in relation to
women’s issues is surprisingly poor. Little to nothing is known about zonisamide, retigabine/ezogabine,
lacosamide, perampanel and the other new AEDs. Nevertheless, many small studies and case series have
been published on new AEDs and women-speciﬁc aspects. This review gives an overview on what is
known today.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Antiepileptic drugs (AEDs) are widely used. They are prescribed
as standard treatment not only for epilepsies, but for a variety of
nonepileptic conditions as well, mainly bipolar spectrum disorders
and chronic pain states.1,2 In fact, only one out of three AED
users takes these drugs for epilepsy.3,4 A large number of AEDs are
available. Since 1990, 16 new (or ‘‘second-generation’’) AEDs
have been registered: lamotrigine, vigabatrin, tiagabine, felba-
mate, topiramate, gabapentin, pregabalin, levetiracetam, zonisa-
mide, stiripentol, oxcarbazepine, eslicarbazepine, ruﬁnamide,
lacosamide, retigabine, and perampanel. In many countries,
women constitute the majority of users of these new AEDs.5–7
This may be due to special, women-related safety and tolerability
issues, but as well to the epidemiology of certain disease states.8,9
During the past 20 years, much attention has been directed
toward AEDs and women. Hormonal and metabolic disturbances
induced by AEDs, as well as teratogenic and adverse cognitive
effects in the offspring of women with epilepsy have come into the* Correspondence to: St. Olavs Hospital, Department of Clinical Pharmacology,
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interactions with hormonal contraception, the menstrual cycle,
pharmacokinetic changes during pregnancy, breast-feeding, and
menopause have also received growing attention.14–18 Many
studies on these issues have been conducted with the classic
AEDs, mainly valproate and carbamazepine. With respect to the
newer antiepileptic drugs however, only lamotrigine appears to
be comparably well-studied. Other new AEDs have been
examined only in part, or not at all.
Generally, and with only few exceptions (e.g., felbamate
and vigabatrin), the new AEDs possess favorable safety
proﬁles compared to the classic AEDs. Especially concerning
hormone-related issues and teratogenicity, the new AEDs appear
to come out better than the older AEDs.19 Accordingly, the use of
new AEDs by fertile women has increased considerably.20
Many of the studies discussed in this review, although useful, are
small and do not qualify as basis for sound clinical guidelines. Their
results should be reproduced by further, and preferably larger,
studies. In fact, there are still too many gaps in our knowledge
and much research remains to be done. Nonetheless, this review
aims to give a brief yet concise overview on what is currently known,
and what is not, on the clinical pharmacokinetics of new AEDs in
women. Possible effects on the offspring of women treated with
new AEDs (teratogenic or cognitive) will not be covered.served.
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2.1. Endogenous female sex hormones
Female sex hormones can roughly be divided into estrogens and
progestogens, and both of them can be of endogenous or
exogenous origin. Estrogens have long been seen as pro-convulsive
compounds while progestogens are generally thought to have anti-
convulsive effects.21–25 While this implies a theoretical possibility
of pharmacodynamic interactions with AEDs, things are not that
simple. Estrogens may have neuroprotective and anti-convulsive
effects as well. Their effects may depend on the body’s general
hormonal state, and ﬂuctuations in the serum level ratio between
estrogens and progestogens also seem to be of great relevance for
the biological effects of estrogens.25 Thus, with our limited
knowledge, any net effect of the theoretical pharmacodynamic
interactions between estrogens, progestogens and AEDs would be
difﬁcult to evaluate or predict.
Pharmacokinetic effects of endogenous female sex hormones on
new AEDs are most relevant with respect to the menstrual cycle and
pregnancy. These issues are discussed in separate sections below.
There are only very few studies on how new AEDs may exert
effects on endogenous female sex hormones. Oxcarbazepine has
been reported to decrease endogenous estrogen by 50% and
progesterone by 58%.26 For lamotrigine, only small and hardly
clinically relevant changes (reduced estradiol and increased
progesterone) have been found.27 Levetiracetam does not seem to
induce changes in female sex hormone status inprepubertal children
or adult women.28,29 There seem to be no published human studies
investigating possible effects of topiramate, gabapentin, pregabalin
or any of the other new AEDs on endogenous female sex hormones.
2.2. Exogenous female sex hormones
Exogenous female sex hormones are predominantly used in
hormonal contraception and in hormonal replacement therapy
(HRT). These are discussed in separate sections.
2.3. Endogenous male sex hormones
Women do produce male sex hormones. The most important
ones are testosterone, androstendione, and dihydroepiandroster-
one (DHEA). Alterations in their production may have signiﬁcant
consequences, e.g. disturbed metabolism or impaired fertility.
Testosterone is metabolised to estradiol by aromatase, and it
has been assumed that levetiracetam may inhibit aromatase. If this
is true, patients on levetiracetam may have raised testosterone
levels, accompanied by reduced estradiol levels. In fact, this has
been found in an in vitro study.30 However, the only available
study that investigated androgen and estrogen levels in women
using levetiracetam found no differences vs. untreated controls.28
Lamotrigine apparently does not alter testosterone levels
when compared to untreated controls or valproate-treated
patients.28,31,32 However, slightly reduced androstendione (22%)
and elevated DHEA (30%) levels have been reported.28
Oxcarbazepine reduces testosterone levels by 25%, while DHEA
and androstendione levels go up by 30% and 20%.26
In conclusion, with the exception of oxcarbazepine’s effects on
estradiol and progesterone, the impact of new AEDs on endoge-
nous hormones – as far as they have been studied – seems to be
rather moderate.
2.4. Sex hormone binding globulin
Sex hormone binding globulin (SHBG) is a liver-derived
glycoprotein that transports sex hormones and regulates theiraccess to target tissues.33 AED-induced changes in SHBG levels
may thus be relevant for sex hormone functioning and homeosta-
sis. Lamotrigine has been shown not to affect SHBG levels
signiﬁcantly,27,28,32,34 although Hill et al.27 and Sidhu et al.34
found lowered values in lamotrigine-treated women vs. controls.
Likewise, levetiracetam does not seem to affect SHBG levels.28 By
contrast, oxcarbazepine increases SHBG by 10–20%. This effect
may contribute to the lower levels of estradiol and progesterone
found with oxcarbazepine treatment.26 No data on SHBG in women
are available for the other new AEDs.
3. Menstrual cycle
Estradiol up-regulates the expression of uridinediphosphate-
glucuronosyltransferase (UGT) 1A4.35 This enzyme catalyzes the
metabolism of lamotrigine, and also retigabine/ezogabine. As
shown by Sidhu et al.34 (discussed below), the estrogen-mediated
induction of UGT1A4 vanishes within a few days after stopping the
intake of ethinyl estradiol containing contraceptives, and lamo-
trigine serum concentrations may double within one week.
Similarly, physiological serum concentrations of endogenous
estradiol vary considerably during the menstrual cycle. Extrapo-
lating the ﬁndings of Sidhu et al.34 one might expect similar ups
and downs of lamotrigine levels. However, several studies show
that ﬂuctuating serum concentrations of endogenous estradiol or
progesterone during the menstrual cycle do not affect lamotrigine
serum concentrations in a clinically relevant manner.36–38 Neither
retigabine/ezogabine (also a UGT-substrate) nor any of the other
new AEDs have been studied in this regard. However, during the
luteal phase of the menstrual cycle, renal blood ﬂow, glomerular
ﬁltration rate and body water may increase by up to 10%.39 As is the
case with, e.g. serum sodium or serum albumin, serum concentra-
tions of most drugs, especially those with primarily renal
elimination (e.g., gabapentin, pregabalin or levetiracetam) may
decline accordingly, i.e. by a magnitude of 5–10%. Such changes are
so small that they have to be regarded as clinically irrelevant.
Unfortunately, as mentioned above, there is a substantial lack of
data supporting these considerations.
4. Hormonal contraception
4.1. Effects of new AEDs on hormonal contraception
It is well known that traditional AEDs like phenytoin or
carbamazepine can reduce the effect of hormonal contraception
via induction of cytochome enzymes. Thus, it has become standard
procedure during the development of new AEDs to examine
their possible effects on hormonal contraception. Many of the
new AEDs have been tested for possible impairment of hormonal
contraception (Table 1). Lamotrigine, levetiracetam, gabapentin,
zonisamide, lacosamide, perampanel and retigabine do not alter
the serum concentrations of ethinyl estradiol.34,40–46 Also, with the
exception of lamotrigine and perampanel, they do not affect the
serum concentrations of exogenous progestogens like levonorges-
trel.34,40 The effect of the latter two AEDs on progestogen levels
seems to be rather modest. However, the possibility of decreased
contraceptive efﬁcacy cannot be excluded.47,48 Oxcarbazepine
and eslicarbazepine reduce exposure to both ethinyl estradiol
and progestogens considerably, making hormonal contraception
unreliable.49,50 Topiramate is a moderate enzyme inducer. It has
been examined in two studies, and in neither of them did it affect
the kinetics of progestogens. With respect to ethinyl estradiol, one
of these studies found no effect at daily topiramate doses of 50, 100
and 200 mg. However, the other study examined daily doses of
200, 400 and 800 mg, and here the maximum ethinyl estradiol
Table 1
Effects of hormonal contraception and new antiepileptic drugs on each other.
Effect on:
AED Ethinylestradiol Progestogen Reference
Lamotrigine #40–60%a $ #19% 31,48,49
Levetiracetam $ $ $ 42,50
Oxcarbazepine n.a. #47% #47% 45
Eslicarbazepine n.a. #30–40% #40% 44
Topiramate n.a. #18–30%/$ $ 46,47
Gabapentin n.a. $ $ 40
Pregabalin n.a. n.a. n.a.
Zonisamide $ $ $ 41,43
Lacosamide $ $ $ 38
Retgabine/
ezogabine
$ $ $ 39
Stiripentol n.a. n.a. n.a.
Perampanel n.a. $ #40% 37
$ No effect; n.a. = no data available.
a Lamotrigine reduced by ethinylestradiol-containing contraceptives.
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800 mg daily.51,52
4.2. Effects of hormonal contraception on new AEDs
Sabers et al.53 and others34,54 demonstrated that oral contra-
ceptives containing ethinyl estradiol can reduce the serum
concentration of lamotrigine by over 50%, leading to breakthrough
seizures and requiring dose adjustment. Progestogen-only contra-
ceptives do not seem to affect lamotrigine pharmacokinetics
signiﬁcantly.54 Despite its clinical relevance, this kind of drug
interaction has received only modest attention. Levetiracetam,
zonisamide, lacosamide and (somewhat surprising with regard to
its UGT-mediated metabolism) retigabine/ezogabine have been
found not to be affected by hormonal contraceptives.41,42,44,45,55
No studies on the other new AEDs are available (Table 1).
5. Pregnancy
During pregnancy, signiﬁcant changes in several physiological
functions occur56–58 and some of them will affect the pharmaco-
kinetics of drugs given to the pregnant patient.15,16,59 The most
relevant changes are
(a) an increase by 50–80% of renal blood ﬂow shortly after
conception
(b) a massive increase in the serum concentration of endogenous
estrogens and
(c) an increase in total body water and fat stores
Renal blood ﬂow increases signiﬁcantly as early as two weeks
after conception and may lead to accelerated renal elimination of
drugs, especially those that are excreted mainly unchanged
through the kidneys. Raised estrogen levels lead to changes in
metabolic capacity: dependent on the isoform, both increased and
decreased activities of cytochome P450 (CYP) enzymes have been
found. More importantly, raised estrogen induces the activity of
UGT enzymes considerably.35,58 This may lead to clinically relevant
alterations in drug metabolism. Increased total body water and
body fat may result in larger volumes of distribution and lower
AED serum concentrations. Also, serum albumin concentrations
decline considerably during pregnancy. However, lowered serum
albumin usually affects drugs that are highly protein bound
(>90%), leading to increases in their free (=pharmacologically
active) fraction. Of the new AEDs, this applies to tiagabine and
stiripentol. Unfortunately, no data on the course of their serumconcentrations during pregnancy are available.60 In addition to
these changes, frequent vomiting makes drug absorption uncertain
in many women.
The physiological changes induced by pregnancy are usually
reversed within 1–2 weeks after childbirth. Changes in drug
metabolism and elimination will also be reversed within this time
frame, and serum concentrations that declined during pregnancy
will rise after delivery. If dose adjustments were made during
pregnancy, they must be reversed shortly, in order to prevent
overdosing. Therapeutic drug monitoring is recommended.59,61
Lamotrigine is by far the best studied of all the new AEDs. Its
serum concentrations decline by 40–60% during pregnancy, and
most of this decline occurs already within the ﬁrst trimester. Loss
of seizure control occurs in up to 58% of pregnant women, and dose
adjustment often becomes necessary.62–71 Both increased renal
elimination and increased metabolism contribute to this ef-
fect.62,65,72 Serum concentrations turn back to pre-pregnancy
levels within one to two weeks after delivery. An easy-to-follow
algorithm for dose adjustment during pregnancy and its reversal
after childbirth has been developed.61
Levetiracetam serum concentrations fall by 40–60% during
pregnancy, most presumably due to accelerated renal elimina-
tion.59,73,74 After delivery, concentrations raise to pre-pregnancy
levels within one week.73
Topiramate concentrations decline by 30–40%, most likely due
to accelerated renal elimination.75,76 No serum concentrations
have been measured within the ﬁrst weeks after delivery, but one
should expect a rapid reversal of pregnancy-induced changes in
topiramate elimination, i.e. within 1–2 weeks.
Oxcarbazepine, or more precisely: its active metabolite
licarbazepine (formerly called monohydroxyderivative, or MHD),
declines by 30–40%.77–79 The most active enantiomer of licarba-
zepine, S-licarbazepine (marketed as eslicarbazepine acetate), has
not been studied separately. Because eslicarbazepine obviously
follows the same elimination pathways as licarbazepine (i.e.,
mainly glucuronidation), a similar decline of its serum concentra-
tions should be expected. This is supported by stereoselective
measurements performed in a series of ﬁve patients treated with
oxcarbazepine by Mazzucchelli et al.77 In this case series, serum
concentrations of S-licarbazepine increased 1.5–13-fold within a
few days after delivery. A similar trend was seen for R-
licarbazepine.
Zonisamide has not been studied systematically, but two case
reports suggest that serum concentrations fall by 20–40% during
pregnancy.80,81 In one of these cases, the plasma concentration was
measured after childbirth, and it rose by 45% within 9 days
postpartum.80
Data on other new AEDs in pregnancy are not available
(Table 2). It appears reasonable to assume that these drugs also
are subject to more or less accelerated elimination from the body.
Especially the serum concentrations of gabapentin, pregabalin
and lacosamide (eliminated mainly unchanged via the kidneys)
and retigabine/ezogabine (eliminated mainly by glucuronidation)
should be expected to decline considerably.
Apart from the physiological changes leading to altered
pharmacokinetics of new AEDs, one should keep in mind that
adherence may have an even greater impact.82 Several studies
have shown that 40–60% of pregnant women do not take their
medication as prescribed, and this has also been found in women
with epilepsy.83–86
6. Breastfeeding
New AEDs, like other drugs, pass over into breast milk, although
to varying degrees according to their individual physicochemical
properties. Only a limited number of small-scaled studies and
Table 2
Changes in the serum concentrations of new antiepileptic drugs during pregnancy.
Reduction
in serum
concentration
Reference
Lamotrigine 50–60% 56–63
Levetiracetam 40–60% 66,67
Oxcarbazepine 30–40% 70–72
Eslicarbazepine n.a.
Topiramate 30–40% 68,69
Gabapentin n.a.
Pregabalin n.a.
Zonisamide 20–40% 73,74
Lacosamide n.a.
Retgabine/ezogabine n.a.
Stiripentol n.a.
Perampanel n.a.
n.a. = no data available.
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been found so far, breastfeeding while taking new AEDs generally
appears to be safe for the child.
Lamotrigine passage from blood into breast milk varies
between 40 and 60%66,87 and correlates with the mother’s dose.88
Neonatal lamotrigine serum concentrations are approximately
equivalent to maternal lamotrigine concentrations at delivery. By
contrast, the ratio of nursed infant/maternal serum lamotrigine
concentrations is much lower and varies greatly, from 0.03 to 0.5.
This does not seem to be related to the infant’s age.63,69,70,88
Possible causes include not only variable lamotrigine concentra-
tions in breast milk, but also large interindividual differences in
UGT1A4-mediated metabolic capacity up to the teen-age years
(the younger the age, the greater the variability).89 Indeed, it has
been suggested that full UGT1A4 activity may not be reached
before almost 19 years of age.90 In sum, over 50 mother/infant
pairs have been documented so far.66,68–70,87,88,91–95With only one
exception, no adverse effects have been noted in these studies. The
exception is a case report that describes an episode of apnoea in a
breastfed child whose mother used a dose of 850 mg lamotrigine
(increased from 450 mg during pregnancy).95 At admission, 16
days postpartum, the infant’s serum concentration was 4.9 mg/ml.
However, on the day of birth and on postpartum day 3, infant
serum concentrations were even higher (7.7 mg/ml and 5.8 mg/
ml), but without any signs of respiratory depression or other
adverse effects. This appears to be the only available report on
acute adverse effects of breastfeeding while using lamotrigine and
it should be noted that the dose used by the mother was relatively
high. The maternal serum concentration on the day after admission
of the infant was 14.9 mg/ml. Hence, the infant/mother serum
concentration ratio was 0.3, which is within the usual range as
reported by other authors. This case underlines the need to
monitor maternal serum concentrations and to reduce the
lamotrigine dose after delivery.
Possible cognitive effects have been investigated in a recent
study with long-term follow-up. No difference in mean IQ
between 30 breastfed and 36 non-breastfed children at age
three years was found.96
Levetiracetam shows extensive transfer into breast milk and in
two studies, the milk/maternal serum concentration ratio aver-
aged around 1. Breast-fed infants had low levetiracetam serum
concentrations, suggesting a rapid elimination of the drug. No
adverse effects were noted.74,97 By contrast, a single case report
described increasing hypotonia and poor suckling in a 7 days
old infant (born pre-term at 34 weeks of gestation) after
levetiracetam had been added to his mother’s treatment regime.
In this case, the milk/plasma ratio was 3.1. No infant serum
concentrations were measured at admission.98From the sparse data available, the milk/maternal plasma
concentration ratio of the active metabolite of oxcarbazepine,
licarbazepine (MHD), is 0.5–0.8.99,100 However, serum concentra-
tions in the reported infants did not exceed 5% of the mother’s
plasma levels and no harmful effects have been reported.99–104
No separate studies on eslicarbazepine have been published.
Limited data suggest that topiramate is safe for breastfeeding.
The milk/maternal plasma concentration ratio averages around
0.9, but serum concentrations in the infants were very low. No
adverse effects on breastfed children have been reported.105,106
Only four mother/infant pairs have been reported with
respect to zonisamide. The calculated milk/maternal serum
concentration ratios ranged from 0.7 to 0.9.80,107,108 No adverse
effects on the breastfed child have been reported. However,
because of the comparably high relative infant dose (about 30%)
reported in these cases, caution and close monitoring of the infant
is advisable.
Gabapentin concentrations in breast milk resemble the
mother’s plasma concentrations, with a milk/plasma ratio of
0.7–1.3. Infant plasma concentrations ranged from 6 to 12% of
the mother’s plasma concentration. No side effects in breastfed
children have been observed, but only six mother/infant pairs
are documented.109,110
There are no studies or case reports on the other new AEDs.
7. Menopause/hormone replacement therapy
Hormone substitution with natural or synthetic estrogens is
very common in postmenopausal women. It has been reported that
50–71% of postmenopausal women with epilepsy experience a
worsening of their seizures, and that the degree of worsening
correlates with the estrogen dose.111 This may be due to endocrine
changes, but may also be a consequence of drug interactions
between exogenous estrogens and AEDs.112
Three studies found lower lamotrigine serum concentrations
and a higher clearance in postmenopausal women.38,112,113 It
might seem obvious that hormone substitution with estrogens
may play a role. However, in one of these studies,38 use of steroid
hormones was an exclusion criterion. Further studies are needed to
clarify this.
One study found that oxcarbazepine clearance does not seem
to be affected by perimenopausal age.114 No further data have
been published.
No other studies on interactions between new AEDs and
menopause or hormone replacement could be identiﬁed.
8. Bone health
Reduced bone mineral density and increased risk of fractures is
a common adverse effect in women after long-term treatment
with traditional AEDs.115,116 Clinical data on the new AEDs are
sparse. While a large retrospective cohort study (n = 15 792)
reported an elevated bone fracture risk for gabapentin but none of
the other new AEDs studied (including lamotrigine, levetiracetam
and oxcarbazepine),117 a smaller study with 560 participants (also
retrospective) concluded that new AEDs are not associated with
lower bone mineral density.118 Other published data as well are
conﬂicting.119–124. However, in an animal model, levetiracetam has
been shown to impair bone quality but not bone density,
suggesting that standard measurement of bone mineral density
may not detect all AED-induced changes in bone health.125 Further,
prospective clinical studies, ideally with clinical outcome param-
eters such as bone fracture frequency, are needed in this ﬁeld
before any conclusions can be drawn.
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Much research has been done, but even more research is needed.
The speed at which new AEDs have been released during the past 20
years has led to a large number of available drugs which we know
relatively little about when it comes to women-speciﬁc questions.
As much as this review has tried to sum up the available knowledge,
it has demonstrated how much we do not know (yet). Compared to
traditional AEDs like phenytoin, phenobarbital or carbamazepine,
most of the new AEDs have a more favorable safety proﬁle even if
some of them may affect hormone homeostasis or can induce serious
adverse effects (e.g. felbamate, vigabatrin). Their clinical pharma-
cokinetics, however, may not be so favorable. Several women-
speciﬁc factors may affect their serum concentration, and for many
clinicians, therapeutic drug monitoring during pregnancy has
virtually become a necessity. Finally, the example of lamotrigine
serum concentrations being reduced by ethinyl estradiol containing
contraceptives (discovered as late as 10 years after lamotrigine came
onto the market) illustrates that future research on new AEDs and
women may proﬁt from new ways to look at things.
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